Kettering Health continues to lead the way in advanced cancer care by offering PLUVICTO^®, the first and only FDA-approved targeted radioactive therapy drug for advanced prostate cancer that binds onto prostate cancer cells and releases radiation directly to those specific cells.

This heightened ability for pinpoint accuracy means treatment is more precise and targeted in its aim to locate and irradicate cancer cells. Studies show that PLUVICTO^® is more effective at delaying cancer progression and increasing overall chances of survival than traditional treatment methods.

“We are excited to offer PLUVICTO^® at Kettering Health because it is a therapy that has become a game changer for patients with advanced prostate cancer who may have failed other types of chemotherapies,” said Dr. Arif Sheikh, nuclear medicine specialist at Kettering Health. “Our goal is to continuously provide our patients with the most advanced therapies that give them the best possible chances of beating cancer.”

Kettering Health administered its first PLUVICTO^® treatment on September 6, 2023. Kettering Health is able to offer PLUVICTO^® through its designation as a nationally recognized Radiopharmaceutical Therapy Clinical Center of Excellence.

One in 8 men will be diagnosed with prostate cancer in their lifetime, making it the most common cancer among men in the United States and a leading cause of cancer-related death. However, it can often be treated successfully when detected early. Kettering Health and the Cincinnati Bengals are committed to providing people with the tools they need to help them better understand early detection and ensure they have access to the resources they need to reduce their cancer risk.